Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has received final approval from the FDA on its abbreviated new drug application for Ipratropium Bromide and Albuterol Sulfate inhalation solution in the 0.5 mg/3mg strength.
Subscribe to our email newsletter
Watson’s Ipratropium Bromide and Albuterol Sulfate product is the generic equivalent to Dey’s DuoNeb, which is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) in patients requiring more than one bronchodilator. Watson intends to launch its Ipratropium Bromide and Albuterol Sulfate product immediately.